7/29/2013

Current evidence does not show that glucagon-like peptide-1 agonists increase the risk of pancreatitis and pancreatic-duct metaplasia in patients with type 2 diabetes, the European Medicines Agency's Committee for Medicinal Products for Human Use indicated. "However, the number of events is too small to draw final conclusions. Due to their mechanism of action, some uncertainties remain in respect to the long-term effect of these medicines on the pancreas, and more data collection efforts are under way," the agency stated.

Related Summaries